Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kaleo Ede

Pediatric Rheumatology Phoenix, AZ Medical Doctor

NPI 1619058260 CMS profile 300469

1920 E Cambridge Ave, Suite 200, Phoenix, AZ 85006

Open in the dashboard

General payments

$11,924

108 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$25,365 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Kaleo Ede of Phoenix, AZ is reported in the CMS Open Payments database as having received $11,924 across 108 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $25,365 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Pediatric Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,616 19
2024 General $630 17
2023 General $323 12
2022 General $1,130 17
2021 General $415 11
2020 General $200 11
2019 General $2,609 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kaleo Ede
  • Pediatric Rheumatology median
  • Middle half of Pediatric Rheumatology
  • National median

In program year 2025, general payments to Kaleo Ede were reported at $6,616. Among 204 Pediatric Rheumatology profiles paid that year, the median was $146 and the middle half received between $95 and $522.

Show as a table
Year Kaleo Ede Pediatric Rheumatology median Middle half National median
2019 $2,609 $141 $61–$1,029 $163
2020 $200 $113 $33–$419 $114
2021 $415 $189 $61–$1,640 $132
2022 $1,130 $120 $28–$404 $149
2023 $323 $97 $41–$222 $160
2024 $630 $139 $48–$606 $164
2025 $6,616 $146 $95–$522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sobi, Inc $6,440 10 payments
  2. Novartis Pharmaceuticals Corporation $2,214 5 payments
  3. Pfizer Inc. $899 9 payments
  4. GlaxoSmithKline, LLC. $580 14 payments
  5. AbbVie, Inc. $558 22 payments
  6. Amgen Inc. $479 25 payments
  7. Aurinia Pharma U.S., Inc. $406 5 payments
  8. Sandoz Inc. $76 3 payments
  9. Alexion Pharmaceuticals, Inc. $74 4 payments
  10. E.R. Squibb & Sons, L.L.C. $35 2 payments
  11. Other $163 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $7,404 2 payments
  2. Food and Beverage $3,112 103 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $740 1 payment
  4. Travel and Lodging $668 2 payments
Products named General payments · program years 2019–2025
  1. GAMIFANT $6,440 10 payments
  2. ILARIS $2,144 2 payments
  3. XELJANZ $899 9 payments
  4. BENLYSTA $580 14 payments
  5. LUPKYNIS $406 5 payments
  6. HUMIRA $282 12 payments
  7. RINVOQ $259 9 payments
  8. Enbrel Inflammation $165 9 payments
  9. Enbrel Inflammation $137 7 payments
  10. Enbrel Inflammation $71 4 payments
  11. Other $620 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

108 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Rheumatology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record